Antiretroviral treatment-based cost saving interventions may offset expenses for new patients and earlier treatment start

HIV Medicine

Volumn 15, Issue 3, 2014, Pages 165-174

  Angeletti, C ^a   Pezzotti, P ^b   Antinori, A ^a   Mammone, A ^a   Navarra, A ^a   Orchi, N ^a   Lorenzini, P ^a   Mecozzi, A ^c   Ammassari, A ^a   Murachelli, S ^a   Ippolito, G ^a   Girardi, E ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b Laziosanità Agency for Public Health Lazio Region   (Italy)

^c Pharmaceutical Department   (Italy)

Author keywords

Antiretroviral therapy; Health care costs; HIV infection; Mathematical model; Treatment guidelines

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE; GENERIC DRUG; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR;

ADOLESCENT; ADULT; AGED; ARTICLE; BUDGET; COST CONTROL; COST OF ILLNESS; COST UTILITY ANALYSIS; DRUG COST; FEMALE; HEALTH CARE COST; HEALTH CARE FINANCING; HEALTH CARE UTILIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ITALY; MALE; MATHEMATICAL MODEL; MIDDLE AGED; MONOTHERAPY; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANTIRETROVIRAL THERAPY; HEALTH CARE COSTS; HIV INFECTION; MATHEMATICAL MODEL; TREATMENT GUIDELINES;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COST SAVINGS; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; ITALY; MALE; MIDDLE AGED; MODELS, THEORETICAL; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84893742213     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12097     Document Type: Article

References (51)

1. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372: 293-299.
2. Antiretroviral Therapy Cohort Collaboration, Zwahlen M, Harris R, May M etal. Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. Int J Epidemiol 2009; 38: 1624-1633.
3. Freedberg KA, Losina E, Weinstein MC etal. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 2001; 344: 824-831.
4. Walensky RP, Paltiel AD, Losina E etal. The survival benefits of AIDS treatment in the United States. J Infect Dis 2006; 194: 11-19.
5. Schackman BR, Gebo KA, Walensky RP etal. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care 2006; 44: 990-997.
6. Sloan CE, Champenois K, Choisy P etal. Cost-Effectiveness of Preventing AIDS Complications (CEPAC) investigators. Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults. AIDS 2012; 26: 45-56.
7. Mandalia S, Mandalia R, Lo G etal. Rising population cost for treating people living with HIV in the UK, 1997-2013. PLoS ONE 2010; 5: e15677.
8. Rizzardini G, Restelli U, Bonfanti P etal. The cost of HIV disease in Northern Italy: the payer's perspective. J Acquir Immune Defic Syndr 2011; 57: 211-217.
9. Gebo KA, Fleishman JA, Conviser R etal. Contemporary costs of HIV healthcare in the HAART era. AIDS 2010; 24: 2705-2715.
10. Krentz HB, Gill MJ. Cost of medical care for HIV-infected patients within a regional population from 1997 to 2006. HIV Med 2008; 9: 721-730.
11. Krentz HB, Gill MJ. Impact of practice changes on an antiretroviral budget in an HIV care program. Dis Manage Health Outcomes 2005; 13: 209-217.
12. Kitahata MM, Gange SJ, Abraham AG etal. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360: 1815-1826.
13. When To Start Consortium, Sterne JA, May M, Costagliola D etal. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009; 373: 1352-1363.
14. Cohen MS, Chen YQ, McCauley M etal. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365: 493-505.
15. Thompson MA, Aberg JA, Hoy JF etal. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308: 387-402.
16. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://www.aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf (accessed 24 November 2012).
17. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373: 48-57.
18. McKinnon JE, Mellors JW, Swindells S. Simplification strategies to reduce antiretroviral drug exposure: progress and prospects. Antivir Ther 2009; 14: 1-12.
19. Mathis S, Khanlari B, Pulido F etal. Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis. PLoS ONE 2011; 6: e22003.
20. Beck EJ, Mandalia S, Sangha R etal. Lower healthcare costs associated with the use of a single-pill ARV regimen in the UK, 2004-2008. PLoS ONE 2012; 7: e47376.
21. Foreman C, Gazzard B, Johnson M, Sharott P, Collins S. Maintaining cost-effective access to antiretroviral drug therapy through a collaborative approach to drug procurement, consensus treatment guidelines and regular audit: the experience of London HIV commissioners and providers. Sex Transm Infect 2012; 88: 112-115.
22. Mauskopf JA, Sullivan SD, Annemans L etal. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices - budget impact analysis. Value Health 2007; 10: 336-347.
23. Antinori A, Marcotullio S, Ammassari A etal. Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011. New Microbiol 2012; 35: 113-159.
24. Decreto del Presidente in qualità di Commissario ad Acta 14 giugno 2011, n. 45. Razionalizzazione dell'uso dei farmaci per la terapia HIV. Bur Lazio 21 luglio 2011, n. 27 - So n. 142.
25. Suligoi B, Boros S, Camoni L, Lepore D. Aggiornamento delle nuove diagnosi di infezione da HIV e dei casi di AIDS in Italia al 31 dicembre 2011. Not Ist Super Sanità 2012; 25 (10 Suppl 1): 1-47.
26. Marks G, Crepaz N, Janssen RS. Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. AIDS 2006; 20: 1447-1450.
27. Working Group on Estimation of HIV Prevalence in Europe. HIV in hiding: methods and data requirements for the estimation of the number of people living with undiagnosed HIV. AIDS 2011; 25: 1017-1023.
28. Mammone A, Pezzotti P, Navarra A, Angeletti C, Orchi N, Girardi E. How many persons are living with undiagnosed HIV infection? An estimate for Lazio Region, Italy, based on surveillance data. 4th Italian Conference on AIDS and Retroviruses. Naples, Italy, June 2012 [Abstract no. OC 10].
29. Orchi N, Balzano R, Scognamiglio P etal. Ageing with HIV: newly diagnosed older adults in Italy. AIDS Care 2008; 20: 419-425.
30. Mammone A, Pezzotti P, Angeletti C etal. HIV incidence estimate combining HIV/AIDS surveillance, testing history information and HIV test to identify recent infections in Lazio, Italy. BMC Infect Dis 2012; 12: 65.
31. d'Arminio Monforte A, Cozzi Lepri A, Rezza G etal. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients. AIDS 2000; 14: 499-507.
32. Lohse N, Hansen AB, Pedersen G etal. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007; 146: 87-95.
33. Keiser O, Taffé P, Zwahlen M etal. All cause mortality in the Swiss HIV Cohort Study from 1990 to 2001 in comparison with the Swiss population. AIDS 2004; 18: 1835-1843.
34. Trotta MP, Lorenzini P, Ammassari A etal. Prescription patterns and cost of combination antiretroviral therapy (CART) in an italian clinical care setting. 1st Italian Conference on AIDS and Retroviruses. Milan, Italy, 2009 [Abstract no. PP 07].
35. French Hospital Database on HIV. Retour d'Informations Clinico-Epidémiologiques (RICE) - février 2013. Available at http://www.ccde.fr/_fold/fl-1364308704-649.pdf (accessed 3 April 2013).
36. Health Protection Agency. HIV in the United Kingdom: 2012 Report. London, Health Protection Services, Colindale, 2012. Available at http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317137200016 (accessed 3 April 2013).
37. Hamers FF, Phillips AN. Diagnosed and undiagnosed HIV-infected populations in Europe. HIV Med 2008; 9 (Suppl 2): 6-12.
38. Savage EJ, Lowndes CM, Murphy G etal. Use of laboratory tests to study non-disclosure of HIV status within the Unlinked Anonymous Survey in GUM clinics. 17th annual British HIV Association conference. Bournemouth, UK, April 2011 [Abstract no. O13].
39. Long EF, Brandeau ML, Owens DK. The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States. Ann Intern Med 2010; 153: 778-789.
40. Mauskopf J, Kitahata M, Kauf T, Richter A, Tolson J. HIV antiretroviral treatment: early versus later. J Acquir Immune Defic Syndr 2005; 39: 562-569.
41. Beck EJ, Mandalia S, Lo G etal. Cost-effectiveness of early treatment with first-line NNRTI-based HAART regimens in the UK, 1996-2006. PLoS ONE 2011; 6: e20200.
42. Schackman BR, Scott CA, Sax PE etal. Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial. Clin Infect Dis 2007; 45: 1062-1070.
43. Stoll M, Kollan C, Bergmann F etal. Calculation of direct antiretroviral treatment costs and potential cost savings by using generics in the German HIV ClinSurv cohort. PLoS ONE 2011; 6: e23946.
44. Gazzard B, Hill A, Anceau A. Cost-efficacy analysis of the MONET trial using UK antiretroviral drug prices. Appl Health Econ Health Policy 2011; 9: 217-223.
45. Pulido F, Pérez-Valero I, Delgado R etal. Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression. Antivir Ther 2009; 14: 195-201.
46. Lambert-Niclot S, Flandre P, Valantin MA etal. Factors associated with virological failure in HIV-1-infected patients receiving darunavir/ritonavir monotherapy. J Infect Dis 2011; 204: 1211-1216.
47. Arribas JR, Clumeck N, Nelson M, Hill A, van Delft Y, Moecklinghoff C. The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV-1 RNA copies/mL at baseline. HIV Med 2012; 13: 398-405.
48. Walensky RP, Sax PE, Nakamura YM etal. Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med 2013; 158: 84-92.
49. Llibre JM, Arribas JR, Domingo P etal. Clinical implications of fixed-dose coformulations of antiretrovirals on the outcome of HIV-1 therapy. AIDS 2011; 25: 1683-1690.
50. Ledergerber B, Cavassini M, Battegay M etal. Trends over time of virological and immunological characteristics in the Swiss HIV Cohort Study. HIV Med 2011; 12: 279-288.
51. Cambiano V, Lampe FC, Rodger AJ etal. Long-term trends in adherence to antiretroviral therapy from start of HAART. AIDS 2010; 24: 1153-1162.